Agios Pharmaceuticals Inc (STU:8AP)
€ 56 0 (0%) Market Cap: 3.20 Bil Enterprise Value: 2.30 Bil PE Ratio: 5.18 PB Ratio: 2.06 GF Score: 28/100

Q3 2024 Agios Pharmaceuticals Inc Earnings Call Transcript

Oct 31, 2024 / 12:00PM GMT
Operator

Good morning and welcome to Agios third quarter, 2024 conference call. (Operator Instruction). Please be advised that today's call is being recorded at Agios requests. And I'd like to turn the call over to Chris Taylor, Vice President, Investor Relations and corporate communications for Agios.

Christopher Taylor
Agios Pharmaceuticals Inc - Vice President, Investor Relations and Corporate Communications

Thank you, operator. Good morning, everyone and welcome to Agios conference call and webcast to discuss our third quarter, 2024 financial results and recent business highlights. You can access the slides for today's call by going to the investors section of our website Agios.com, on today's call. I'm joined by our Chief Executive Officer, Brian Goff, Doctor Sarah Gheuens, Chief Medical Officer, and head of R&D, Tsveta Milanova, Chief Commercial Officer and Cecilia Jones, Chief Financial Officer.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements, actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot